Brief: Sirnaomics Receives IND Clearance From FDA For Phase I Clinical Study Of RNAI Therapeutic
12/04/2023 02:18
April 12 (Reuters) - Sirnaomics Ltd 2257.HK :
* RECEIVES IND CLEARANCE FROM U.S. FDA FOR- PHASE I CLINICAL
STUDY
OF RNAI THERAPEUTIC STP122G
Source text for Eikon: ID:
Further company coverage: 2257.HK
Recent news on Sirnaomics
See all newsBrief: Sirnaomics Announces RMB30 Million Capital Injection For Deemed Disposal
Brief: Sirnaomics And Unit Files Writ Of Summons Against Former Management
Brief: Sirnaomics To Issue 2.4 Million New Shares At Hk$4.69 Each Under General Mandate
Brief: Sirnaomics Says Chairman Purchases 38,000 Shares At Average Price Hk$5.93 Per Share
Brief: Sirnaomics Ltd To Issue 17.4 Million Subscription Shares